Introduction and welcome (ID 4881)
Optimising patient outcomes with adjuvant Osimertinib: Improving patient identification through non-smoking related NSCLC screening and EGFR reflex testing (ID 4882)
Panel discussion: what outcomes should we expect in early stage NSCLC: the importance of targeting the right patients with the right treatment (ID 4883)
Shaping first-line clinical practice with third-generation EGFR-TKIs in patients with metastatic EGFRm NSCLC (ID 4884)
Panel discussion: Learnings from real-world practice in first-line metastatic EGFRm NSCLC (ID 4885)
